Read More

Reported Earlier, Inhibikase Therapeutics Issues A Letter To Shareholders And Comments On Recent Trading Activity; Says ‘Unusually High Volume and Steep Declines in Price Have Impacted the Stock With No Identifiable Cause

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"),

IKT